JTI Korea Expands Sales of Ploom X Advanced Device

JTI by 2FIRSTS.ai
Feb.04.2025
JTI Korea Expands Sales of Ploom X Advanced Device
JTI expands sales of "Ploom X Advanced" heating tobacco device to Coupang and Naver platforms for broader consumer access.

According to a report by N. News on February 3rd, Japan Tobacco International's (JTI) South Korea Company announced that sales of its heated tobacco device, "Ploom X Advanced," will be expanded to include the third-party e-commerce platforms Coupang and Naver.


Since its launch in November 2024, "Ploom X Advanced" has begun selling on the "JTI Korea" page on the Coupang platform and the "Ploom Store" on Naver. Consumers can purchase devices in four colors including Slate Grey, Navy Blue, Black, and Silver through these platforms, with a discount of 40,000 Korean Won (approximately $30).


A spokesperson from JTI Korea stated that the reason for expanding sales channels is to allow "more consumers to experience the modern enjoyment brought by Ploom X Advanced through multiple platforms." They plan to launch a variety of new products such as new cigarette sticks and accessories in February.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

UK Tobacco and Vapes Bill Enters House of Lords Report Stage
UK Tobacco and Vapes Bill Enters House of Lords Report Stage
The Tobacco and Vapes Bill has entered the report stage in the UK House of Lords, with further examination scheduled to begin on February 24, 2026. The legislation aims to create the first “smoke-free generation” by ensuring that individuals who are 15 years old or younger in 2026 can never legally be sold tobacco.
Regulations
Feb.22
Moldova adopts new sanitary rules for tobacco products, e-cigarettes and related goods
Moldova adopts new sanitary rules for tobacco products, e-cigarettes and related goods
Moldova is introducing new sanitary standards for tobacco products, e-cigarettes and related goods, with regulations adopted on January 14 aimed at protecting public health and tightening control over tobacco sales. The rules include measures to limit minors’ access to tobacco products, including via online shops, and establish procedures for notifications, reporting and market monitoring.
Jan.16 by 2FIRSTS.ai
Report: 43% of 546 Canadian specialty vape shops found non-compliant in federal inspections
Report: 43% of 546 Canadian specialty vape shops found non-compliant in federal inspections
Health Canada’s vaping compliance and enforcement report covering inspections from April 2024 to March 2025 found 43% of 546 specialty vaping businesses were not compliant with the Tobacco and Vaping Products Act and the Canada Consumer Product Safety Act, according to the report cited. Health inspectors seized vaping products at 235 specialty vaping establishments.
Feb.26 by 2FIRSTS.ai
Korea’s MFDS sets 2026 plan to manage and disclose harmful constituents in tobacco products
Korea’s MFDS sets 2026 plan to manage and disclose harmful constituents in tobacco products
South Korea’s Ministry of Food and Drug Safety (MFDS) said it has established its 2026 work plan to systematically manage harmful constituents in tobacco products and disclose related information under the Tobacco Harmfulness Management Act, which took effect in November 2025.
Jan.16 by 2FIRSTS.ai
Study: Links between internalizing mental health symptoms and nicotine/tobacco use vary by gender identity among U.S. adolescents
Study: Links between internalizing mental health symptoms and nicotine/tobacco use vary by gender identity among U.S. adolescents
A study using 2020–2023 U.S. data from the ITC Youth Tobacco and Vaping Survey (ages 16–19) reports that both nicotine/tobacco use and internalizing mental health (IMH) symptoms vary across disaggregated gender identities, and that gender identity moderates the relationship between IMH symptoms and product use.
Feb.27 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11